Expansion momentum Serán is actively expanding its manufacturing footprint in Bend, Oregon, with a CGMP facility and a new 100,000-square-foot commercial campus planned to open in Fall 2027. This signals increased capacity for large-scale production and a potential need for scalable process development, quality systems integration, and supply chain partnerships.

Funding-backed growth The company has secured substantial investment and strategic growth funding from Bain Capital Life Sciences, Vivo Capital, and Biospring Partners, including a recent $200M transaction. This indicates strong financial backing, enabling accelerated clinical-to-commercial manufacturing services and potential collaborations on large-scale programs.

Spray dry leadership Serán emphasizes advanced particle engineering and spray drying capabilities to tackle poorly soluble compounds, offering services from discovery through clinical materials to commercial supply. This creates opportunities to partner on complex formulation challenges, inhalation therapies, and high-value solid-dose programs.

Full-service partnership With end-to-end capabilities spanning predictive design tools, novel chemistry, analytical support, regulatory compliance, and manufacturing, Serán positions itself as a one-stop partner for clients seeking seamless transition from discovery to clinic and beyond, particularly for small and large molecules with solubility challenges.

Talent and capacity The company reports over 200 employees, including more than 150 scientists and engineers, highlighting a strong technical bench and potential for rapid project execution. This depth supports scalable engagements for large pharma and biotech programs requiring robust R&D and manufacturing expertise.